Max W. Sung
Mount Sinai Hospital
29 Papers
37 Citations
Max W. Sung is an academic researcher from Mount Sinai Hospital. The author has contributed to research in topics: Lenvatinib & Sorafenib. The author has an hindex of 11, co-authored 29 publications.
Chat about Author
Papers
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Richard S. Finn,Masafumi Ikeda,Andrew X. Zhu,Max W. Sung,Ari David Baron,Masatoshi Kudo,Takuji Okusaka,Masahiro Kobayashi,Hiromitsu Kumada,Shuichi Kaneko,Marc Pracht,Konstantin Mamontov,Tim Meyer,Tomoki Kubota,Corina E. Dutcus,Kenichi Saito,Abby B. Siegel,Leonid Dubrovsky,Kalgi Mody,Josep M. Llovet,Josep M. Llovet +20 more
TL;DR: Lenvatinib plus pembrolizumab has promising antitumor activity in uHCC, and toxicities were manageable, with no unexpected safety signals.
Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis.
Sasan Roayaie,Jonathan D. Schwartz,Max W. Sung,Sukru Emre,Charles M. Miller,Gabriel Gondolesi,Nancy Krieger,Myron Schwartz +7 more
TL;DR: Recurrence of HCC significantly shortens survival after transplant, and some patients with recurrence can be expected to live for a considerable period of time, although surgery is independently associated with longer survival.
459
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Arndt Vogel,Shukui Qin,Masatoshi Kudo,Yun Su,Stacie Hudgens,Tatsuya Yamashita,Jung Hwan Yoon,Laetitia Fartoux,Krzysztof Simon,Carlos F. Lopez,Max W. Sung,Kalgi Mody,Tatsuroh Ohtsuka,Toshiyuki Tamai,Lee Bennett,Genevieve Meier,V. Breder +16 more
TL;DR: In this paper, the authors evaluated the effect of treatment with lenvatinib versus sorafenib on health-related quality of life (HRQOL) in patients undergoing treatment for unresectable hepatocellular carcinoma.
101
Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein
Jonathan D. Schwartz,Myron Schwartz,Deborah Lehrer,E. Cohen,Max W. Sung,M. Kinkhabwala,Abby B. Siegel,S. Holloway,Allyson J. Ocean,Scott Wadler +9 more
TL;DR: Bvacizumab can be given safely at both 5 mg/kg and 10mg/kg in HCC patients with localized, unresectable HCC, preserved liver function and no significant esophageal varices, and preliminary results suggest significant disease-modifying effect.
62
Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma.
Arndt Vogel,Catherine Frenette,Max W. Sung,Bruno Daniele,Ari David Baron,Stephen L. Chan,Jean-Frédéric Blanc,Toshiyuki Tamai,Min Ren,Howard John Lim,Daniel H. Palmer,Yuko Takami,Masatoshi Kudo +12 more
TL;DR: Better liver function at baseline, as measured by ALBI grade or CPS, may be prognostic for better survival outcomes in patients with uHCC undergoing treatment with lenvatinib or sorafenib.